AbbVie Inc
USUSDAbbVie Inc (XETRA:4AB) — Biotechnology: Pharmaceutical Preparations. Število borz, na katerih se trgujejo delnice družbe: 4. Na tej strani — cena in graf, dividende, največji imetniki in zgodovina števila delnic.
O Podjetju
- Spletna Stran
- abbvie.com
- Sektor
- Health Care · Biotechnology: Pharmaceutical Preparations
- Sedež
- North Chicago, United States
- Izvršni Direktor
- Robert A. Michael
- Zaposleni
- 57 000
- Ustanovljena
- 2012
- Na Borzi od
- 17.05.2016 (XETRA:4AB)
- Delnice v Obtoku
- Prosto Prenosljive Delnice
- 1.76 mrd.
- Tržna Kapitalizacija
- 470.55 mrd. USD
- Notranje Osebe
- 0.11%
- Institucionalni Vlagatelji
- 77.37%
- Panoga (SIC)
- Pharmaceutical Preparations
- Pravna Oblika
- XTIQ
- ISIN
- US00287Y1091
- LEI
- FR5LCKFTG8054YNNRU85
- P/E
- 80.6
- Delež Izplačila
- 190%
- FCF
- 18.2 mrd. USD
- Izplačilo / FCF
- 66%
- Dolg
- 70.8 mrd. USD3.5 let FCF
- Dividendni Staž
- 13 let
- Dobički, FCF in izplačane dividende — za 12 mesecev do 30.06.2026 (najnovejše poročilo podjetja).
- NAV
Opis
AbbVie Inc., a research-based biopharmaceutical company, engages in the research and development, manufacturing, commercializing, and sale of medicines and therapies worldwide. The company offers Skyrizi to treat autoimmune diseases; Rinvoq to treat inflammatory diseases; Imbruvica for the treatment of adult patients with blood cancers; Venclexta to treat blood cancers; Elahere to treat various cancer; and Epkinly to treat lymphoma; and Emrelis for the treatment of lung cancer. It also provides facial injectables, plastics and regenerative medicine, body contouring, and skincare products; botox Cosmetic for the treatment of glabellar lines, crow's feet, forehead lines, and platysma bands; Juvederm Collection to treat volume loss in the temples, undereye, cheeks, chin, lips and lower face; Vraylar to treat schizophrenia, bipolar disorder, and depressive disorder; Duodopa to treat Parkinson's disease; Ubrelvy to treat migraine; Qulipta for episodic and chronic migraine; and Vyalev for the treatment of motor fluctuations, as well as Botox Therapeutic to treat chronic migraine, overactive bladder, spasticity, cervical dystonia, and other conditions. In addition, the company offers Ozurdex for visual impairment; Lumigan/Ganfort and Alphagan/Combigan for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension; and other eye care products, including Refresh/Optive, Xen, Durysta, and Restasis. Further, it provides Mavyret to treat chronic hepatitis C virus genotype 1-6 infection; Creon, a pancreatic enzyme therapy; and Linzess/Constella to treat irritable bowel syndrome with constipation and chronic idiopathic constipation. The company was incorporated in 2012 and is headquartered in North Chicago, Illinois.
Dividende
AbbVie Inc (4AB) izplačuje dividende četrtletno. Na leto (12 mesecev do in vključno z najnovejšim napovedanim plačilom): 4.5646 EUR na delnico (plačila: 3). To je približno 1.86% trenutne cene delnice. Glede na zgodovino izplačil se naslednji datum ex-dividende pričakuje okoli 13.01.2027. Leta neprekinjenih dividend: 13.
| Ex-Datum | Izplačilo | Znesek | % | Vrsta | Oznaka |
|---|---|---|---|---|---|
| 2026-07-15 | — | 1.5215 EUR | 0.7/2.8 % | četrtletno | XETRA:4AB |
| 2026-04-15 | — | 1.5215 EUR | 0.9/3.4 % | četrtletno | XETRA:4AB |
| 2026-01-16 | — | 1.5215 EUR | 0.8/3.1 % | četrtletno | XETRA:4AB |
| 2025-10-15 | — | 1.4424 EUR | 0.7/2.9 % | četrtletno | XETRA:4AB |
| 2025-07-15 | — | 1.4424 EUR | 0.9/3.5 % | četrtletno | XETRA:4AB |
| 2025-04-15 | — | 1.4424 EUR | 0.9/3.6 % | četrtletno | XETRA:4AB |
| 2025-01-15 | — | 1.4424 EUR | 0.8/3.3 % | četrtletno | XETRA:4AB |
| 2024-10-15 | — | 1.3632 EUR | 0.8/3.0 % | četrtletno | XETRA:4AB |
| 2024-07-15 | — | 1.3632 EUR | 0.9/3.4 % | četrtletno | XETRA:4AB |
| 2024-04-12 | — | 1.3632 EUR | 0.9/3.4 % | četrtletno | XETRA:4AB |
| 2024-01-12 | — | 1.3632 EUR | 0.9/3.5 % | četrtletno | XETRA:4AB |
| 2023-10-12 | — | 1.3017 EUR | 0.9/3.7 % | četrtletno | XETRA:4AB |
| 2023-07-13 | — | 1.3017 EUR | 1.1/4.2 % | četrtletno | XETRA:4AB |
| 2023-04-13 | — | 1.3017 EUR | 0.9/3.4 % | četrtletno | XETRA:4AB |
| 2023-01-12 | — | 1.3017 EUR | 0.9/3.5 % | četrtletno | XETRA:4AB |
| 2022-10-13 | — | 1.2401 EUR | 0.9/3.4 % | četrtletno | XETRA:4AB |
| 2022-07-14 | — | 1.2401 EUR | 0.8/2.5 % | četrtletno | XETRA:4AB |
| 2022-04-13 | — | 1.2401 EUR | 0.8/1.6 % | četrtletno | XETRA:4AB |
| 2022-01-13 | — | 1.2401 EUR | 1.0/1.0 % | četrtletno | XETRA:4AB |
Novice Ta Teden
Sporočila za javnost s spletne strani za vlagatelje podjetja, ki se dnevno posodabljajo. Povezave vodijo na spletno stran podjetja. Naslovi so v izvirnem jeziku, kot na spletni strani podjetja.
Največji Imetniki
| Imetnik | Delež | Delnice | Datum Poročila |
|---|---|---|---|
| BlackRock | 8.46% | 149.49 mio. | 2026-06-30 |
| Vanguard Capital Managem… | 6.53% | 115.4 mio. | 2026-06-30 |
| State Street Corporation | 4.67% | 82.6 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 3.17% | 56.09 mio. | 2026-06-30 |
| Vanguard Portfolio Manag… | 2.74% | 48.48 mio. | 2026-06-30 |
| JPMORGAN CHASE & CO | 2.71% | 47.86 mio. | 2026-06-30 |
| Geode Capital Management… | 2.66% | 47 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 2.59% | 45.78 mio. | 2026-06-30 |
| Morgan Stanley | 2.2% | 38.9 mio. | 2026-06-30 |
| Capital Research Global… | 1.7% | 30.1 mio. | 2026-06-30 |
| NORGES BANK | 1.45% | 25.55 mio. | 2026-06-30 |
| iShares Trust-iShares Co… | 1.35% | 23.84 mio. | 2026-08-31 |
| Fidelity Concord Street… | 1.29% | 22.85 mio. | 2026-07-31 |
| SPDR S&P 500 ETF TRUST-S… | 1.22% | 21.61 mio. | 2026-08-31 |
| Bank of America Corporat… | 1.2% | 21.24 mio. | 2026-06-30 |
| VANGUARD INDEX FUNDS-Van… | 0.95% | 16.82 mio. | 2026-06-30 |
| SELECT SECTOR SPDR TRT-S… | 0.72% | 12.7 mio. | 2026-08-31 |
| AMERICAN MUTUAL FUND | 0.63% | 11.15 mio. | 2026-07-31 |
| Capital Income Builder | 0.57% | 10.06 mio. | 2026-07-31 |
| VANGUARD SPECIALIZED FUN… | 0.57% | 10 mio. | 2026-07-31 |
| GONZALEZ RICHARD A (Dire… | ≈0.02% | 386 479 | 2025-03-31 |
| SALEKI-GERHARDT AZITA (C… | ≈0.01% | 220 682 | 2026-02-18 |
| MICHAEL ROBERT A. (Chief… | ≈0.01% | 215 260 | 2026-02-18 |
| FREYMAN THOMAS C (Direct… | ≈0.01% | 135 751 | 2026-05-08 |
| STEWART JEFFREY RYAN (Of… | ≈0.01% | 108 321 | 2026-02-18 |
| DONOGHOE NICHOLAS (Offic… | ≈0% | 74 430 | 2026-08-14 |
| REENTS SCOTT T. (Chief F… | ≈0% | 60 415 | 2026-02-18 |
| THAKKAR ROOPAL (Officer) | ≈0% | 60 413 | 2026-02-18 |
| TILTON GLENN FLETCHER (D… | ≈0% | 51 914 | 2025-05-09 |
| RAPP EDWARD J (Director) | ≈0% | 45 964 | 2026-05-08 |
| The Vanguard Group | — | — | — |
